NCT06084767 is a NA clinical trial of 68Ga-TCR-FAPI PET/CT in Malignant Tumor, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences.

Who is sponsoring NCT06084767?

NCT06084767 is sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences.

What drugs are being tested in NCT06084767?

Interventions in NCT06084767: 68Ga-TCR-FAPI PET/CT.

What condition does NCT06084767 study?

NCT06084767 studies Malignant Tumor, Positron Emission Tomography, Fibroblast Activation Protein Inhibitor.

Is NCT06084767 still recruiting?

NCT06084767 is currently status unknown. Last updated 23 October 2023.

Last reviewed 2023-10-23 · How we verify

NCT06084767

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

68Ga-TCR-FAPI PET/CT in Patients With Various Types of Cancer

Status unknown NA Last updated 23 October 2023

What this trial tests

NA trial testing 68Ga-TCR-FAPI PET/CT in Malignant Tumor in 60 participants. Status unknown.

Timeline

5 May 2023

Primary endpoint
30 April 2025

30 December 2025

Quick facts

Lead sponsor	Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	60
Start date	5 May 2023
Primary completion	30 April 2025
Estimated completion	30 December 2025
Sites	1 location across China

Drugs / interventions tested

68Ga-TCR-FAPI PET/CT

Conditions studied

Malignant Tumor — all drugs for Malignant Tumor →
Positron Emission Tomography — all drugs for Positron Emission Tomography →
Fibroblast Activation Protein Inhibitor — all drugs for Fibroblast Activation Protein Inhibitor →

Sponsor

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Who can join

18 and older, any sex, with Malignant Tumor or Positron Emission Tomography. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Adding targeted covalent radiopharmaceutical (TCR) moiety to fibroblast activation protein inhibitor (FAPI) can increase tumor uptake and tumor retention in pre-clinical studies. This study is an open-labeled single-arm phase II diagnostic clinical trial to explore the clinical value of 68Ga-TCR-FAPI PET/CT in suspected malignant tumor patients.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

CTR-FAPI PET Enables Precision Management of Medullary Thyroid Carcinoma.
Kong Z, Li Z, Cui XY, Wang J, et al · · 2025 · cited 14× · PMID 39470165 · DOI 10.1158/2159-8290.cd-24-0897

Verify or expand the search:

Other recruiting trials for Malignant Tumor

Currently open trials in the same condition.

NCT07193329 — Psychological Distress in Malignant Tumor Patients: Effects on Treatment Adherence, Outcomes, and Quality of Life · recruiting
NCT06618274 — Effectiveness of Central Oncology Navigation and the Use of an ORN · NA · recruiting
NCT06674889 — Rehabilitation Outcomes Study · NA · recruiting
NCT05862259 — A Real-world Study of the Efficacy and Safety of ICIs as First-line Therapy for Advanced Malignancies · recruiting
NCT05596344 — Long-term Follow-up of Anxiety and Depression in Patients With Malignant Tumors · recruiting

Other Cancer Institute and Hospital, Chinese Academy of Medical Sciences trials

Trials by the same sponsor.

NCT07531563 — Protein Supplementation for Radiation- Induced Oral Mucositis in Head and Neck Cancer Patients Receiving Radiotherapy · NA · not yet recruiting
NCT07537049 — BR101 in Patients With Relapsed/Refractory Multiple Myeloma · Phase 1 · not yet recruiting
NCT07187154 — The Application of Symptoms Management Program Based on the Patient Reported Outcome After Esophagectomy · NA · not yet recruiting
NCT07530549 — A Phase II Single-arm Clinical Study in the Treatment of Locally Advanced Esophageal Cancer After Failed Neoadjuvant Che · Phase 2 · not yet recruiting
NCT07507058 — Hypofractionated Radiotherapy for Postoperative Intermediate-Risk Head and Neck Squamous Cell Carcinoma · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06084767 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Last refreshed: 23 October 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06084767.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing